The NH-BMT and Leukemia Programs are committed to publishing in the field of blood and marrow transplantation, Leukemia and hematologic malignancies. The following publications/presentations demonstrate this commitment.

2025 ASTCT Tandem Meeting Oral and Poster Presentations:

Collaborative Oral Presentations:

CAR and ALL Hematotox Scores Predict Toxicity and Outcomes Among Recipients of Brexucabtagene Autoleucel for R/R ALL in the Real World Outcomes Collaborative of CAR-T in Adult ALL (ROCCA) Consortium- Yannis Valtis, Jacob Boccucci, Timothy O'Connor, David Nemirovsky, Matthew Connor, Noam Kopmar, Talal Hilal, Simone Dekker, Noelle Frey, Abdullah Ladha, Clayton Jackson, Marc Schwartz,Vamsi Kota, Sean Devlin, Omer Jamy, Marlise Luskin, Amy Zhang, Vinod Pullarkat, Ali Al Darobi, LaQuisa Hill, Paul Shaughnessy, Shahbaz Malik, Caitlin Guzowski, John Mathews, Michael Daunov, Evandro Bezerra, Divya Koura, Jae Park, Jozal Moore, Kristen O'Dwyer, Evan Chen,Vivian Gatell, Vishal Gupta Angeles, Chenyu Lin, Luke Mountjoy, Muthu Kumaran, Wendy Stock, Ryan Cassaday, Sean Tracy, Mohamed Ahmed, Matthew Ulrickson, Michael Grunwald, Katharine Miller, Katherine Sutherland, Ran Reshef, Joshua Sasine, Kaitlyn Dykes, Anjali Advani, Bijal Shah, Rasmus Hoeg, Caspian Oliai,Maria Odstrcil Bobillo, Nikeshan Jeyakumar, George Yaghmour, Minoo Battiwalla, Veronika Bachanova, Catherine Lee, Gregory Roloff, Lori Muffly, Navneet Majhail, Sumithira Vasu,Ibrahim Aldoss, Aaron Logan, Melhem Solh, Rawan Faramand, Tamer Othman, Ibrahim Muhsen, Bhagirathbhai Dholaria, Olalekan Oluwole, Stephanie Tsai, Jessica Leonard

TSC-100 and TSC-101 Demonstrate the Potential to Reduce Relapse Rates and Increase Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT) with Reduced Intensity Conditioning (RIC): Preliminary Results from the Phase 1 Alloha Trial (NCT05473910)-Rawan Faramand, Abdullah Ladha, Jacob Boccucci, Jessica Leonard,Noelle Frey, Timothy O'Connor, Tamer Othman, Virginia Tan, Ibrahim Aldoss, Stephanie Tsai, Matthew Connor, Noam Kopmar,Talal Hilal,Ryan Cassaday,Maria Odstrcil Bobillo ,Lori Muffly, Marc Schwartz, Ali Al Darobi, Vamsi Kota, Kristen O'Dwyer, Amy Zhang, Paul Shaughnessy, Shahbaz Malik, Melhem Solh, Caitlin Guzowski, John Mathews, Divya Koura, Chenyu Lin, Jozal Moore, Aaron Logan, Minoo Battiwalla, Luke Mountjoy, Matthew Ulrickson, Katharine Miller, Nikeshan Jeyakumar, Katherine Sutherland, Catherine Lee, Navneet Majhail, Gregory Roloff, George Yaghmour, Kaitlyn Dykes, Anjali Advani, Bijal Shah, Maryann Stefan

Program Poster Presentations:

Allogeneic Hematopoietic Cell Transplantation (HCT) for TP53-Mutated MDS/AML- Time to be Selective-Melhem Solh, Scott Solomon, Asad Bashey, Lizamarie Bachier-Rodriguez, Lawrence Morris, Joyce Izundu, H. Kent Holland 

Improved Outcomes with Primary Graft Failure Patients in the Current Era of Timely Access to Haploidentical Donors-Melhem Solh, Katelin Jackson, Scott Solomon, Asad Bashey, Lizamarie Bachier-Rodriguez, Lawrence Morris, H. Kent Holland, Xu Zhang 

NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free Survival-Yannis Valtis, Jacob Boccucci, Timothy O'Connor, David Nemirovsky, Matthew Connor, Noam Kopmar Hilal, Simone Dekker, Noelle Frey, Abdullah Ladha, Clayton Jackson, Marc Schwartz,Vamsi Kota, Sean Devlin, Omer Jamy, Marlise Luskin, Amy Zhang, Vinod Pullarkat, Ali Al Darobi, LaQuisa Hill, Paul Shaughnessy, Shahbaz Malik, Caitlin Guzowski, John Mathews, Michael Daunov, Evandro Bezerra, Divya Koura, Jae Park, Jozal Moore, Kristen O'Dwyer,Evan Chen, Vivian Gatell, Vishal Gupta, Chenyu Lin, Luke Mountjoy, Muthu Kumaran, Wendy Stock, Ryan Cassaday, Sean Tracy, Mohamed Ahmed,Matthew Ulrickson, Michael Grunwald, Katharine Miller, Katherine Sutherland, Ran Reshef, Joshua Sasine, Kaitlyn Dykes, Anjali Advani, Bijal Shah, Rasmus Hoeg, Caspian Oliai, Maria Odstrcil Bobillo, Nikeshan Jeyakumar, George Yaghmour, Minoo Battiwalla, Veronika Bachanova, Catherine Lee ,Gregory Roloff, Lori Muffly, Navneet Majhail, Sumithira Vasu, Ibrahim Aldoss, Aaron Logan, Melhem Solh,Rawan Faramand, Tamer Othman, Ibrahim Muhsen, Bhagirathbhai Dholaria, Olalekan Oluwole, Stephanie Tsai, Jessica Leonard

Allogeneic Hematopoietic Cell Transplant Following Standard of Care Brexucabtagene Autoleucel (Brexu-cel) in Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA),Rawan Faramand- Jacob Boccucci, Timothy O'Conno, Virginia Tan, Matthew Connor, Noam Kopmar,Talal Hilal, Noelle Frey, Abdullah Ladha, Marc Schwartz, Vamsi Kota, Kristen O'Dwyer, Amy Zhang, Ali Al Darobi, Paul Shaughnessy, Shahbaz Malik, Caitlin Guzowski, John Mathews, Divya Koura, Jozal Moore, Chenyu Lin, Luke Mountjoy, Ryan Cassaday, Matthew Ulrickson, Katharine Miller, Katherine Sutherland, Kaitlyn Dykes, Anjali Advani, Bijal Shah, Maryann Stefan, Maria Odstrcil Bobillo, Nikeshan Jeyakumar, George Yaghmour, Minoo Battiwalla, Catherine Lee, Gregory Roloff, Lori Muffly, Navneet Majhail, Ibrahim Aldoss, Aaron Logan, Melhem Solh, Tamer Othman, Stephanie Tsai, Jessica Leonard

Tyrosine Kinase Inhibitor (TKI) Maintenance Improves Remission Durability in Philadelphia-Chromosome Acute Lymphoblastic Leukemia (Ph+ ALL) Following Brexucabtagene Autoleucel (Brexu-cel)-Tamer Othman, Timothy O'Connor, Virginia Tan, Matthew Connor, Noam Kopmar, Talal Hilal, Noelle Frey, Abdullah Ladha, Marc Schwartz, Kristen O'Dwyer, Amy Zhang,Vinod Pullarkat, LaQuisa Hill, Paul Shaughnessy, Shahbaz Malik,Caitlin Guzowski, John Mathews, Divya Koura, Jozal Moore, Chenyu Lin, Luke Mountjoy, Ryan Cassaday, Mohamed Ahmed, Katharine Miller, Josh Sasine, Katherine Sutherland, Kaitlyn Dykes, Anjali Advani, Bijal Shah, Maryann Stefan, Maria Odstrcil Bobillo , Nikeshan Jeyakumar, George Yaghmour, Minoo Battiwalla, Catherine Lee, Gregory Roloff, Lori Muffly, Navneet Majhail, Ibrahim Aldoss, Aaron Logan, Melhem Solh, Rawan Faramand, Ibrahim Muhsen, Stephanie Tsai, Jessica Leonard

Lisocabtagene Maraleucel (liso-cel) in Patients (Pts) with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL): Results from the Final Analysis of the MCL Cohort of the Open-Label, Phase 1, Seamless Design, Multicenter Transcend NHL 001 (TRANSCEND) Study- Michael Wang, Scott Solomon, Jeremy Abramson, Matthew Lunning, Manali Kamdar, Charalambos Andreadis, M. Lia Palomba, Nilanjan Ghosh, Alexandre Hirayama, Jing Wang, Amitkumar Mehta, Jon Arnason, Leo Gordon, Ashvin Singh, Tanya Siddiqi, Giovanna Andreola

Circulating Tumor DNA (ctDNA) As an Early Outcome Predictor in Patients (Pts) with Second-Line (2L) Large B-Cell Lymphoma (LBCL) after Lisocabtagene Maraleucel (lisocel) Versus Standard of Care (SOC) Treatment (Tx) from the Phase 3, Randomized Transform Study- Lara Stepan, Ash Alizadeh, David Kurtz, Scott Solomon, Justine Dell’Aringa, Jeremy Abramson, Patrick Johnston, Manali Kamdar, Jacob Chabon, Victor Chow, Sahar Ansari, Ethan Thompson, Leanne Peiser, Abood Okal, Sami Ibrahimi, Jon Arnason, Francisco Hernandez-Ilizaliturri, Veronika Bachanova, Mazyar Shadman, Bertram Glass, Koji Izutsu, Pim Mutsaers, Stephan Mielke, Alessandro Crotta 

KMT2Ar Adversely Impacts Brexucabtagene Autoleucel (Brexu-cel) Outcome in Adults with Relapsed/ Refractory (r/r) B-Cell Acute Lymphoblastic Leukemia- Jessica Leonard, Jacob Boccucci, Evan Chen, Timothy O'Connor, Virginia Tan, Matthew Connor), Noam Kopmar, Talal Hilal, Noelle Frey, Olalekan Oluwole, Divya Koura, Vamsi Kota ,Marlise Luskin, Kristen O'Dwyer, Amy Zhang, Vinod Pullarkat, Ali Al Darobi, LaQuisa Hill, Paul Shaughnessy, Shahbaz Malik, Caitlin Guzowski, John Mathews, Evandro Bezerra, Jae Park,Jozal Moore (Rochester, USA),Vishal Gupta (Los Angeles, USA),Chenyu Lin (Durham, USA),Luke Mountjoy (Denver, USA),Muthu Kumaran (Little Rock, USA),Wendy Stock (Chicago, USA),Ryan Cassaday (Seattle, USA),Sean Tracy (Minneapolis, USA),Mohamed Ahmed (Los Angeles, USA),Matthew Ulrickson (Gilbert, USA),Katharine Miller (Stanford, USA),Katherine Sutherland (Stanford, USA),Ran Reshef (New York, USA),Joshua Sasine (Los Angeles, USA),Kaitlyn Dykes (La Jolla, USA),Anjali Advani (Cleveland, USA),Bijal Shah (Tampa, USA), Rasmus Hoeg, Maryann Stefan, Caspian Oliai, Maria Odstrcil Bobillo, Nikeshan Jeyakumar, George Yaghmour, Minoo Battiwalla, Veronika Bachanova, Catherine Lee, Gregory Roloff, Lori Muffly, Navneet Majhail, Abdullah Ladha, Yannis Valtis, Sumithira Vasu, Ibrahim Aldoss, Aaron Logan, Melhem Solh, Rawan Faraman , Tamer Othman, Ibrahim Muhsen, Bhagirathbhai Dholaria, Stephanie Tsai 

Administration of Low-Dose, Subcutaneous (SC) Interleukin-2 (IL-2) Markedly Enhances the Pharmacokinetic (PK) Profile of Azercabtagene Zapreleucel (azer-cel), an Allogeneic Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, without Compromising Safety and Early Evidence of Clinical Activity in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Who Have Relapsed after Prior CD19-Directed CAR T-Cell Products- John Byon, Scott Solomon, Houston Holmes, Edmund Waller, Adam Olszewski, Nirav Shah, Bijal Shah, Alex Herrera, Joseph Maakaron, Rajneesh Nath, Vladimir Senyukov,Tilanthi Jayawardena, Sharon Yavro